Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06144606
Status:
RECRUITING
Last Update Posted:
2024-05-09
First Post:
2023-11-16
Brief Title:
Study of KTE-X19 in Minimal Residual Disease MRD Positive B-Cell Acute Lymphoblastic Leukemia B-ALL
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Phase 2 Study of KTE-X19 in Minimal Residual Disease MRD Positive B-Cell Acute Lymphoblastic Leukemia B-ALL
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia B-ALL participants in remission with minimal residual disease MRD after KTE-X19 CAR T-cell therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None